About Spruce Biosciences, Inc.
https://www.sprucebiosciences.comSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
CEO
Javier Szwarcberg
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-05 | Reverse | 1:75 |
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Citizens
Market Outperform
JMP Securities
Market Outperform
Leerink Partners
Outperform
RBC Capital
Sector Perform
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RIVERVEST VENTURE MANAGEMENT LLC
Shares:2.94M
Value:$230.12M
ABINGWORTH LLP
Shares:1.79M
Value:$140.48M
BLACKROCK INC.
Shares:124.73K
Value:$9.78M
Summary
Showing Top 3 of 5
About Spruce Biosciences, Inc.
https://www.sprucebiosciences.comSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8.23M ▲ | $-8.21M ▼ | 0% | $-14.58 ▼ | $-8.19M ▼ |
| Q2-2025 | $0 | $2.69M ▼ | $-2.07M ▲ | 0% | $-3.41 ▲ | $-2.03M ▲ |
| Q1-2025 | $0 ▼ | $14.49M ▼ | $-14.04M ▲ | 0% ▲ | $-24 ▲ | $-14M ▲ |
| Q4-2024 | $697K ▲ | $24.77M ▲ | $-23.56M ▼ | -3.38K% ▼ | $-43.5 ▼ | $-23.49M ▼ |
| Q3-2024 | $602K | $10.01M | $-8.67M | -1.44K% | $-16.5 | $-8.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $10.67M ▼ | $15.31M ▼ | $9.93M ▲ | $5.39M ▼ |
| Q2-2025 | $16.39M ▼ | $21.82M ▼ | $8.64M ▼ | $13.18M ▼ |
| Q1-2025 | $25.61M ▼ | $31.65M ▼ | $16.32M ▼ | $15.32M ▼ |
| Q4-2024 | $38.75M ▼ | $45.21M ▼ | $16.39M ▲ | $28.82M ▼ |
| Q3-2024 | $60.05M | $65.1M | $13.46M | $51.64M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.21M ▼ | $-5.32M ▲ | $0 | $-402K ▼ | $-5.72M ▲ | $-5.32M ▲ |
| Q2-2025 | $-2.07M ▲ | $-8.83M ▲ | $0 | $-400K ▲ | $-9.23M ▲ | $-8.83M ▲ |
| Q1-2025 | $-14.04M ▲ | $-12.73M ▲ | $0 | $-411K ▲ | $-13.14M ▲ | $-12.73M ▲ |
| Q4-2024 | $-23.56M ▼ | $-20.68M ▼ | $0 | $-625K ▼ | $-21.3M ▼ | $-20.68M ▼ |
| Q3-2024 | $-8.67M | $-9.22M | $0 | $-405K | $-9.63M | $-9.22M |
CEO
Javier Szwarcberg
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-05 | Reverse | 1:75 |
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Citizens
Market Outperform
JMP Securities
Market Outperform
Leerink Partners
Outperform
RBC Capital
Sector Perform
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RIVERVEST VENTURE MANAGEMENT LLC
Shares:2.94M
Value:$230.12M
ABINGWORTH LLP
Shares:1.79M
Value:$140.48M
BLACKROCK INC.
Shares:124.73K
Value:$9.78M
Summary
Showing Top 3 of 5